Results 51 to 60 of about 127,263 (196)

Structural changes in intestinal enteroendocrine cells after ileal interposition in normal rats [PDF]

, 2011
INTRODUCTION: No therapeutic approach has significantly impacted the progression of diabetes. As early improvement of glicaemic control is observed after bariatric surgeries, there is currently a search for surgical procedures that can promote euglycemia
Aparecida Hirata, Bianca Marigliani, Gilmara Aguiar-Yamaguchi, Gustavo Miguel, José-Francisco Borborema, João-Luiz Azevedo, João-Luiz Azevedo, João-Luiz Azevedo, Karina Neves, Linda Bernardes, Lucas Leal, Marcelo Carlini, Maria Alves, Otavio Azevedo, Paolo Lourenco, Rudy Rocha, Wellington Cardia   +16 more
core   +2 more sources

Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents [PDF]

, 2017
peer-reviewedThe gut hormone glucagon-like peptide (GLP)-1 and its analogues represent a new generation of anti-diabetic drugs, which have also demonstrated propensity to modulate host lipid metabolism.
Cryan, John F., Dinan, Timothy G., Kent, Robert M., Mandal, Rupasri, Murphy, Kiera, O’Connor, Paula M., Patterson, Elaine, Peterson, Veronica L., Ross, R Paul, Ryan, Paul M, Seeley, Randy J., Stack, Helena, STANTON, CATHERINE, Wishart, David S.   +13 more
core   +5 more sources

The extrapancreatic effects of glucagon-like peptide-1 and related peptides [PDF]

, 2009
Context: Glucagon-like peptide-1 (GLP-1) 7-36 amide, an insulinotropic hormone released from the intestinal L cells in response to nutrient ingestion, has been extensively reviewed with respect to -cell function.
Abu Hamdah, Rania, Rabiee, Atoosa, Meneilly, Graydon S., Shannon, Richard P., Andersen, Dana K., Elahi, Dariush   +5 more
core   +1 more source

Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice

Journal of Diabetes Investigation
Aims/Introduction Imeglimin is a recently approved oral antidiabetic agent that improves insulin resistance, and promotes insulin secretion from pancreatic β‐cells.
Osamu Kikuchi, Yuichi Ikeuchi, Masaki Kobayashi, Yoko Tabei, Hiromi Yokota‐Hashimoto, Tadahiro Kitamura   +5 more
doaj   +1 more source

Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs

Scientific Reports
Insulin secretion is impaired in individuals with cystic fibrosis (CF), contributing to high rates of CF-related diabetes (CFRD) and substantially increasing disease burden. To develop improved therapies for CFRD, better knowledge of pancreatic pathology
Sina A. Gharib, Rachna Vemireddy, Joseph J. Castillo, Brendy S. Fountaine, Theo K. Bammler, James W. MacDonald, Rebecca L. Hull-Meichle, Sakeneh Zraika   +7 more
doaj   +1 more source

Topical administration of GLP-1 eyedrops improves retinal ganglion cell function by facilitating presynaptic GABA release in early experimental diabetes

Neural Regeneration Research
Diabetic retinopathy is a prominent cause of blindness in adults, with early retinal ganglion cell loss contributing to visual dysfunction or blindness.
Yu-Qi Shao, Yong-Chen Wang, Lu Wang, Hang-Ze Ruan, Yun-Feng Liu, Ti-Hui Zhang, Shi-Jun Weng, Xiong-Li Yang, Yong-Mei Zhong   +8 more
doaj   +1 more source

Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]

, 2015
AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo, Dagostino, Mariangela Pia, Fallarino, Mara, Filardi, Tiziana, Lenzi, Andrea, Mandosi, Elisabetta, Morano, Susanna, Nieddu, Luciano, Romagnoli, Elisabetta, Turinese, Irene   +9 more
core   +1 more source

Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion

Cell Reports, 2017
Summary: Glucagon-like peptide 1 (GLP-1) is a hormone released from enteroendocrine L cells. Although first described as a glucoregulatory incretin hormone, GLP-1 also suppresses inflammation and promotes mucosal integrity.
Lorène J. Lebrun, Kaatje Lenaerts, Dorien Kiers, Jean-Paul Pais de Barros, Naig Le Guern, Jiri Plesnik, Charles Thomas, Thibaut Bourgeois, Cornelis H.C. Dejong, Matthijs Kox, Inca H.R. Hundscheid, Naim Akhtar Khan, Stéphane Mandard, Valérie Deckert, Peter Pickkers, Daniel J. Drucker, Laurent Lagrost, Jacques Grober   +17 more
doaj   +1 more source

Direct visualization of glucagon‐like peptide‐1 secretion by fluorescent fusion proteins

Journal of Diabetes Investigation, 2022
Live‐cell imaging with fluorescent proteins (FPs) is a powerful tool for investigating the exocytosis processes of hormones. However, the secretion process of glucagon‐like peptide‐1 (GLP‐1) has not been visualized by FPs, which might be because tagging ...
Atsushi Tsuzuki, Yoichiro Fujioka, Aiko Yoshida, Sayaka Kashiwagi, Maho Amano, Tohru Hira, Akinobu Nakamura, Hideaki Miyoshi, Tatsuya Atsumi, Yusuke Ohba   +9 more
doaj   +1 more source

Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]

, 2014
Adam M.
A. M. Deane, Deane, Deane, Deane, M. Horowitz, Schwartz, Umpierrez   +6 more
core   +1 more source